Company news
Allarity Therapeutics, Inc. news in 2026
Allarity Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
November 18, 2026
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
November 16, 2026
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
November 13, 2026
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
October 30, 2026
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
September 30, 2026
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
September 28, 2026
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
September 15, 2026
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
September 11, 2026
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
August 14, 2026
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
July 6, 2026
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
June 30, 2026
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
June 18, 2026
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
May 15, 2026
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
May 8, 2026
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 5, 2026
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
April 27, 2026
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
April 21, 2026
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
March 30, 2026
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
March 5, 2026
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
February 18, 2026
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
February 3, 2026
Decks in 2026
- Investor Presentation (May 2026)
Investor deck · 22 slides · May 8, 2026